All In Biotech

Drug Trial Radar · NCT06840886

A Study of PHST001 in Advanced Solid Tumors

An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 426 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

426

Planned (sponsor's estimate)

Start

Mar 31, 2025

Primary completion

Apr 2029

Study completion Apr 2031

Sponsor

Lead sponsor
Pheast TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies. The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.

Conditions

  • Advanced Solid Tumors
  • Ovarian Cancer
  • Endometrial Cancer
  • Cholangiocarcinoma
  • CNS Tumor
  • Breast Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
  • Carcinosarcoma, Ovarian

Interventions

  • PHST001Biological

    PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

  • PaclitaxelDrug

    Paclitaxel used as per standard of care.

  • TopotecanDrug

    Topotecan used as per standard of care.

  • DoxorubicinDrug

    Doxorubicin used as per standard of care.

  • FOLFIRIDrug

    FOLFIRI used as per standard of care.

  • FOLFOXDrug

    FOLFOX used as per standard of care.

  • GemcitabineDrug

    Gemcitabine used as per standard of care.

  • Mirvetuximab SoravtansineBiological

    Mirvetuximab soravtansine used as per standard of care.

  • Trastuzumab DeruxtecanBiological

    Trastuzumab deruxtecan used as per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose of PHST001 through 21 days after the first dose of PHST001
  2. Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From signed consent up to 90 days after the last dose of PHST001
  3. Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  4. Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  5. Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  6. Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  7. Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)Time frame: From screening and during treatment up to 2 years
  8. Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)Time frame: From screening and during treatment up to 2 years

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Precision NextGen Oncology & Research Center

    Beverly Hills, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Stanford University School of Medicine

    Palo Alto, California · Recruiting

  • Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One

    Denver, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • START Center for Cancer Research - Midwest

    Grand Rapids, Michigan · Recruiting

  • START Center for Cancer Research - Long Island New York

    Lake Success, New York · Recruiting

  • Mount Sinai

    New York, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Sarah Cannon Research Institute (SCRI) Oncology Partners

    Nashville, Tennessee · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • START Center for Cancer Research - Texas

    Fort Worth, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology - Dallas

    Irving, Texas · Recruiting

  • START Center for Cancer Research - San Antonio

    San Antonio, Texas · Recruiting

  • University of Texas (UT) Health

    San Antonio, Texas · Recruiting

  • NEXT Oncology - Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.